Related Experiment Video
Updated: May 26, 2026

Histological Quantification to Determine Lung Fungal Burden in Experimental Aspergillosis
Published on: March 9, 2018
Antifungal PK/PD considerations in fungal pulmonary infections
Alexander J Lepak1, David R Andes
1Department of Medicine, University of Wisconsin-Madison School of Medicine and Public Health, Madison, Wisconsin 53705-2281, USA.
Abstract:
Pharmacokinetic/pharmacodynamic (PK/PD) studies examine the relationships of drug pharmacokinetic properties, in vitro drug potency, and treatment efficacy. Study results are integral to the design of optimal dosing strategies, prevention of toxicity, development and interpretation of susceptibility break points, and prevention and recognition of drug resistance. These principles are increasingly utilized to optimize therapy for pulmonary fungal pathogens such as ASPERGILLUS species, although they have been underutilized for other difficult-to-treat fungal pathogens. Understanding the design and implementation of PK/PD studies facilitates more effective utilization of the available antifungal agents to improve outcomes for many of these life-threatening infections.
Related Concept Videos
Impact of Pharmacokinetic–Pharmacodynamic Models: Regulatory Decisions
Antifungal Agents
Pharmacokinetics in Pediatric Patients: Drug Excretion
Pulmonary Tuberculosis V
Latent tuberculosis infection occurs when TB bacteria are present in a person's body, but are not causing illness or symptoms. It is not contagious, and preventive treatment is crucial to avoid the progression...
Pharmacokinetics in Pediatric Patients: Drug Distribution
Fungal Phylum Microsporidia
